Evidence map›Paper›PMID 29692679›Full record

ArticleReproductive medicine and biology2018

Clinical outcomes of assisted reproductive technology treatment by using a self-injection of recombinant human chorionic gonadotropin as the final maturation trigger.

Koji Nakagawa, Midori Oba, Kaori Ehara, Nozomi Ishigaki, Nao Ino, Akiko Itakura, Ryo Tsutsumi, Katsuki Nakao, Yuko Ojiro, Rikikazu Sugiyama

Open access · goldAbstract read
In one paragraph

Article in Reproductive medicine and biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Koji NakagawaDivision of Reproductive Medicine Sugiyama Clinic Tokyo Japan.ORCID 0000-0003-0874-5894
Midori ObaDivision of Reproductive Medicine Sugiyama Clinic Tokyo Japan.
Kaori EharaDivision of Reproductive Medicine Sugiyama Clinic Tokyo Japan.
Nozomi IshigakiDivision of Reproductive Medicine Sugiyama Clinic Tokyo Japan.
Nao InoDivision of Reproductive Medicine Sugiyama Clinic Tokyo Japan.
Akiko ItakuraDivision of Reproductive Medicine Sugiyama Clinic Tokyo Japan.
Ryo TsutsumiDivision of Reproductive Medicine Sugiyama Clinic Tokyo Japan.
Katsuki NakaoDivision of Reproductive Medicine Sugiyama Clinic Tokyo Japan.
Yuko OjiroDivision of Reproductive Medicine Sugiyama Clinic Tokyo Japan.
Rikikazu SugiyamaDivision of Reproductive Medicine Sugiyama Clinic Tokyo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the efficacy and safety of self-injections of the prefilled recombinant human chorionic gonadotropin (r-hCG) in a syringe in assisted reproductive technology (ART) treatment for the maturation trigger (MT), as compared to self-injections of conventional hCG and intranasal administration of gonadotropin-releasing hormone agonist (GnRH-a).

methodsBetween January and April, 2017, 396 patients who underwent oocyte retrieval were recruited. Of these, 396 patients were classified into three groups, according to the types of MT: (1) the urinary human chorionic gonadotropin (u-hCG) group that consisted of patients who had a self-injection of u-hCG (n = 127); (2) the GnRH-a group that received nasal administration of GnRH-a (n = 159); and (3) the r-hCG group that had a self-injection of r-hCG (n = 110). Several ART outcomes were evaluated.

resultsThe mature oocyte retrieval rate was not different between the u-hCG, r-hCG, and GnRH-a groups and the fertilization and cleavage rates were similar between the three groups. The clinical pregnancy rates did not significantly differ between the GnRH-a group and the u-hCG group; however, it was significantly lower in the GnRH-a group, compared to the r-hCG group. No difference was observed in the incidence of moderate or more severe ovarian hyperstimulation syndrome among the three groups.

conclusionThe self-injection of the prefilled r-hCG is a favorable MT for ART patients.

Indexed as

gonadotropin‐releasing hormone analogmaturation triggerovarian hyperstimulation syndromerecombinant human chorionic gonadotrophinurinary human chorionic gonadotropin

Identifiers

PMID29692679
PMCPMC5902473
OpenAlexW2792030015

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.